UPDATE 2-GSK bets $300 mln on genetics as CEO plays down break-up talk


GlaxoSmithKline aims to turbo-charge its drug discovery engine with a big bet on genetics as its CEO on Wednesday played down the idea of hiving off consumer healthcare, which is a source of cash generation for such R&D investment. FILE PHOTO: The GlaxoSmithKline logo is seen on top of GSK Asia House in Singapore, March 21, 2018.



from Biotech News